Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300419 | 0.92 | NR1H2 (0.69) | HSD11B1NR1H2 | |
| SCHEMBL14300414 | 0.89 | NR1H2 (0.73) | HSD11B1NR1H2 | |
| SCHEMBL5564300 | 0.88 | HSD11B1 (0.76) | HSD11B1NR1H2 | |
| SCHEMBL14295064 | 0.87 | NR1H2 (0.63) | HSD11B1NR1H2 | |
| SCHEMBL5564601 | 0.85 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5567960 | 0.85 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5567998 | 0.85 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL4612466 | 0.84 | NR1H2 (0.90) | HSD11B1NR1H2 | |
| SCHEMBL4612817 | 0.83 | NR1H2 (1.00) | HSD11B1NR1H2 | |
| SCHEMBL5568733 | 0.81 | HSD11B1 (0.74) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | claimed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | claimed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | ARSA, SULT2A1, SULT1A1 | HSD11B1 680/4885NR1H2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.